BR112015030419A2 - células aviárias para a produção de vírus melhorado - Google Patents

células aviárias para a produção de vírus melhorado

Info

Publication number
BR112015030419A2
BR112015030419A2 BR112015030419-2A BR112015030419A BR112015030419A2 BR 112015030419 A2 BR112015030419 A2 BR 112015030419A2 BR 112015030419 A BR112015030419 A BR 112015030419A BR 112015030419 A2 BR112015030419 A2 BR 112015030419A2
Authority
BR
Brazil
Prior art keywords
seq
chicken
avian cells
virus production
improved virus
Prior art date
Application number
BR112015030419-2A
Other languages
English (en)
Inventor
Fife Mark
Gibson Mark
Original Assignee
The Pirbright Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Pirbright Institute filed Critical The Pirbright Institute
Publication of BR112015030419A2 publication Critical patent/BR112015030419A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)

Abstract

resumo da patente de invenção para: “células aviárias para a produção de vírus melhorado”. a presente invenção fornece células aviárias em que a expressão ou atividade de um ou mais dos seguintes genes, ou um seu homólogo: ifitm1 de galinha (seq id no 1); ifitm2 de galinha (seq id no 2) e ifitm3 de galinha (seq id no 3) é reduzida. a invenção também fornece métodos para a passagem de vírus em células aviárias, os embriões e / ou linhagens celulares aviárias que tenham a expressão reduzida de um ou mais genes ifitm e métodos que envolvem a investigação da sequência de um ou mais dos seguintes genes, ou um seu homólogo: ifitm1 de galinha (seq id no 1); ifitm2 de galinha (seq id no 2) e ifitm3 de galinha (seq id no 3).
BR112015030419-2A 2013-06-05 2014-06-03 células aviárias para a produção de vírus melhorado BR112015030419A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1310031.8 2013-06-05
GBGB1310031.8A GB201310031D0 (en) 2013-06-05 2013-06-05 Cell
PCT/GB2014/051693 WO2014195692A1 (en) 2013-06-05 2014-06-03 Avian cells for improved virus production

Publications (1)

Publication Number Publication Date
BR112015030419A2 true BR112015030419A2 (pt) 2018-03-27

Family

ID=48805789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030419-2A BR112015030419A2 (pt) 2013-06-05 2014-06-03 células aviárias para a produção de vírus melhorado

Country Status (13)

Country Link
US (2) US10202578B2 (pt)
EP (2) EP3004333B1 (pt)
JP (1) JP6599316B2 (pt)
KR (1) KR102277763B1 (pt)
CN (2) CN110066769B (pt)
AU (1) AU2014276631B2 (pt)
BR (1) BR112015030419A2 (pt)
CA (1) CA2914550A1 (pt)
ES (1) ES2719952T3 (pt)
GB (1) GB201310031D0 (pt)
MX (1) MX366836B (pt)
WO (1) WO2014195692A1 (pt)
ZA (1) ZA201508828B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006373A (es) * 2015-11-24 2018-11-09 Commw Scient Ind Res Org Produccion de virus en cultivos celulares.
WO2017088017A1 (en) * 2015-11-24 2017-06-01 Commonwealth Scientific And Industrial Research Organisation Production of viruses in avian eggs
CN106434649B (zh) * 2016-07-18 2017-08-25 马国辅 一种抗禽传染性支气管炎病毒的肽核酸及应用
CN108085413B (zh) * 2017-12-06 2021-09-21 南京农业大学 一种用于同时检测三种禽病毒病的高通量试剂盒及其检测方法和应用
KR102520151B1 (ko) * 2020-09-11 2023-04-11 전북대학교산학협력단 닭의 ifitm3 단백질에 특이적으로 결합하는 단클론 항체 및 이의 용도
CN113527463B (zh) * 2021-08-20 2023-03-07 广西壮族自治区兽医研究所 Ifitm3蛋白相关物质在制备禽呼肠孤病毒所致疾病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9804283B1 (pt) 1998-03-18 2010-11-30 processo para a produção de flavivìrus em baixa densidade de células em cultura e processo para a produção de flavivìrus recombinante em baixa densidade de células em cultura.
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
BRPI0517742A (pt) * 2004-11-11 2008-10-21 Solvay Pharm Bv método para obter uma partìcula do vìrus da influenza condicionalmente defeituosa, partìcula de vìrus da influenza, célula, composição, uso da mesma, método para gerar proteção imunológica contra infecção de um indivìduo com um vìrus da influenza, uso de uma partìcula, e, métodos para suprir um ácido nucleico que não codifica um peptìdeo da influenza, a uma célula e a um indivìduo
US20100138946A1 (en) 2008-08-14 2010-06-03 Origen Therapeutics Transgenic chickens with an inactivated endogenous gene locus
WO2010125656A1 (ja) * 2009-04-28 2010-11-04 株式会社カネカ 外来性rnaを発現する抗病性トランスジェニック鳥類
BRPI1007744A2 (pt) * 2009-05-12 2017-06-27 Transgene Sa método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas
GB0911794D0 (en) * 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
WO2011072247A2 (en) * 2009-12-11 2011-06-16 The Brigham And Women's Hospital, Inc. Pathogen restriction factors
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
WO2012158985A2 (en) 2011-05-17 2012-11-22 Transposagen Biopharmaceuticals, Inc. Methods for site-specific genetic modification in spermatogonial stem cells using zinc finger nuclease (zfn) for the creation of model organisms
CN102286465B (zh) * 2011-07-08 2012-10-17 华中农业大学 一种抑制口蹄疫病毒增殖的猪ifitm3基因及构建方法和应用

Also Published As

Publication number Publication date
EP3004333B1 (en) 2019-01-16
WO2014195692A1 (en) 2014-12-11
CA2914550A1 (en) 2014-12-11
US10202578B2 (en) 2019-02-12
AU2014276631A1 (en) 2015-12-24
MX2015016765A (es) 2016-08-04
AU2014276631B2 (en) 2020-06-25
US20190203170A1 (en) 2019-07-04
ZA201508828B (en) 2019-04-24
ES2719952T3 (es) 2019-07-17
GB201310031D0 (en) 2013-07-17
MX366836B (es) 2019-07-26
KR102277763B1 (ko) 2021-07-16
CN110066769A (zh) 2019-07-30
US20160108359A1 (en) 2016-04-21
EP3530733A1 (en) 2019-08-28
CN105378073A (zh) 2016-03-02
KR20160012240A (ko) 2016-02-02
CN110066769B (zh) 2024-03-08
JP6599316B2 (ja) 2019-10-30
EP3004333A1 (en) 2016-04-13
JP2016528878A (ja) 2016-09-23

Similar Documents

Publication Publication Date Title
BR112015030419A2 (pt) células aviárias para a produção de vírus melhorado
BR112017005892A2 (pt) variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
EA201790533A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для модулирования экспрессии генов
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
EA201890999A1 (ru) Вакцина против вируса простого герпеса
EA201692535A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201890454A1 (ru) Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
BR112015028605A2 (pt) método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central
BR112015022462A2 (pt) inibidores de ido
EA201691215A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA К КОМПОНЕНТУ КОМПЛЕМЕНТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112017002781A2 (pt) cassete de expressão aprimorado para acondicionamento e expressão de variantes do fator viii para o tratamento de distúrbios de hemostasia
CL2018002905A1 (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucléicos dirigidos.
BR112015022808A2 (pt) método de preparação de farinha integral de alta dispersão com aumento no teor de avenantramida
BR112017011542A2 (pt) produção de ácido oleico em levedura
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
BR112018010503A2 (pt) ovo de ave, método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, ave transgênica, e método para produzir uma ave
BR112015024119A2 (pt) polipeptídeos tendo atividade de fosfolipase a e polinucleotídeos que os codificam
BR112013026447A2 (pt) métodos para a regulação da expressão de gene de sirtuína
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112015023669A2 (pt) novos derivados de ciclosporina e suas utilizações
BR112015021341A2 (pt) anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]